Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

Mohamed L. Sorror*, Brenda M. Sandmaier, Barry E. Storer, Georg N. Franke, Ginna G. Laport, Thomas R. Chauncey, Edward Agura, Richard T. Maziarz, Amelia Langston, Parameswaran Hari, Michael A. Pulsipher, Wolfgang Bethge, Firoozeh Sahebi, Benedetto Bruno, Michael B. Maris, Andrew Yeager, Finn Bo Petersen, Lars Vindeløv, Peter A. McSweeney, Kai HübelMarco Mielcarek, George E. Georges, Dietger Niederwieser, Karl G. Blume, David G. Maloney, Rainer Storb

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

251 Scopus citations


Context: A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions. Objective: To describe outcomes of patients 60 years or older after receiving minimally toxic nonmyeloablative allogeneic HCT. Design, Setting, and Participants: From 1998 to 2008, 372 patients aged 60 to 75 years were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning with low-dose total body irradiation alone or combined with fludarabine, 90 mg/m2, before related (n=184) or unrelated (n=188) donor transplants. Postgraftingimmunosuppression included mycophenolate mofetil and a calcineurin inhibitor. Main Outcome Measures: Overall and progression-free survival were estimated by Kaplan-Meier method. Cumulative incidence estimates were calculated for acute and chronic graft-vs-host disease, toxicities, achievement of full donor chimerism, complete remission, relapse, and nonrelapse mortality. Hazard ratios (HRs) were estimated from Cox regression models. Results: Overall, 5-year cumulative incidences of nonrelapse mortality and relapse were 27% (95% CI, 22%-32%) and 41% (95% CI, 36%-46%), respectively, leading to 5-year overall and progression-free survival of 35% (95% CI, 30%-40%) and 32% (95% CI, 27%-37%), respectively. These outcomes were not statistically significantly different when stratified by age groups. Furthermore, increasing age was not associated with increases in acute or chronic graft-vs-host disease or organ toxicities. In multivariate models, HCT-specific comorbidity index scores of 1 to 2 (HR, 1.58 [95% CI, 1.08-2.31]) and 3 or greater (HR, 1.97 [95% CI, 1.38-2.80]) were associated with worse survival compared with an HCT-specific comorbidity index score of 0 (P=.003 overall). Similarly, standard relapse risk (HR, 1.67 [95% CI, 1.10-2.54]) and high relapse risk (HR, 2.22 [95% CI, 1.43-3.43]) were associated with worse survival compared with low relapse risk (P≲λτ∀.001 overall). Conclusion: Among patients aged 60 to 75 years treated with nonmyeloablative allogeneic HCT, 5-year overall and progression-free survivals were 35% and 32%, respectively.

Original languageEnglish (US)
Pages (from-to)1874-1883
Number of pages10
Issue number17
StatePublished - Nov 2 2011

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies'. Together they form a unique fingerprint.

Cite this